At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Recombinant EphB4-HSA Fusion Protein for Castration Levels of Testosterone and 9 related conditions. Targeting 14 participants across 3 sites.
Detailed Summary
The purpose of this phase II, single-arm, open-label, three center study is to evaluate the efficacy, safety, and tolerability of sEphB4-HSA in patients with mCRPC (metastatic castration-resistant prostate cancer). The study drug, sEphB4-HAS, is a form of protein that has not been approved for sale by the United States Food and Drug Administration (FDA). The study drug prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
Study Details
Timeline
Interventions
Given IV